Evaluation of the VIDAS Anti-HCV Assay for Detection of Hepatitis C Virus Infection
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Anti-hepatitis C virus antibody (anti-HCV) assays are recommended for screening HCV-infected persons. The VIDAS Anti-HCV Assay (bioMérieux, France), based on the enzyme-linked fluorescence test principle, was recently introduced in Korea. We evaluated the clinical performance of the VIDAS assay. Methods: One hundred HCV-positive and 1,002 HCV-negative blood samples confirmed by Architect anti-HCV (Abbott Laboratories, USA) and COBAS TaqMan HCV real-time PCR (Roche Diagnostics, USA) or the Procleix Ultrio Plus Assay (Gen-Probe Incorporated, USA) were obtained from the Human Serum Bank (HSB) and tested by VIDAS. In case of discrepant results, we conducted a recombinant immunoblot assay (RIBA). Results: The agreement rates for known HCV-positive and HCV-negative samples between the VIDAS assay and the HSB testing were 100% (95% confidence interval [CI]: 96.4-100%) and 99.5% (95% CI: 98.8-99.8%), respectively. One of the five discrepant samples was positive for Core 2+ and NS3-2 2+ reactivity, two samples were negative, and the other two were indeterminate regarding NS4 2+ reactivity in RIBA. We observed a significant but weak positive correlation between the titers of VIDAS and Architect assays (r=0.315, P<0.001). Conclusions: The VIDAS anti-HCV assay, developed on the VIDAS automated immunoassay platform based on the ready-to-use, single-sample test concept may be useful in small-to-medium-sized laboratories. It showed good agreement with Architect anti-HCV and COBAS PCR assays and is therefore useful for detection of HCV infection. Weakly test-positive (ambiguous) samples require additional testing by another anti-HCV, RIBA, or HCV RNA assay.
Abstract
Background: Anti-hepatitis C virus antibody (anti-HCV) assays are recommended for screening HCV-infected persons. The VIDAS Anti-HCV Assay (bioMérieux, France), based on the enzyme-linked fluorescence test principle, was recently introduced in Korea. We evaluated the clinical performance of the VIDAS assay. Methods: One hundred HCV-positive and 1,002 HCV-negative blood samples confirmed by Architect anti-HCV (Abbott Laboratories, USA) and COBAS TaqMan HCV real-time PCR (Roche Diagnostics, USA) or the Procleix Ultrio Plus Assay (Gen-Probe Incorporated, USA) were obtained from the Human Serum Bank (HSB) and tested by VIDAS. In case of discrepant results, we conducted a recombinant immunoblot assay (RIBA). Results: The agreement rates for known HCV-positive and HCV-negative samples between the VIDAS assay and the HSB testing were 100% (95% confidence interval [CI]: 96.4-100%) and 99.5% (95% CI: 98.8-99.8%), respectively. One of the five discrepant samples was positive for Core 2+ and NS3-2 2+ reactivity, two samples were negative, and the other two were indeterminate regarding NS4 2+ reactivity in RIBA. We observed a significant but weak positive correlation between the titers of VIDAS and Architect assays (r=0.315, P<0.001). Conclusions: The VIDAS anti-HCV assay, developed on the VIDAS automated immunoassay platform based on the ready-to-use, single-sample test concept may be useful in small-to-medium-sized laboratories. It showed good agreement with Architect anti-HCV and COBAS PCR assays and is therefore useful for detection of HCV infection. Weakly test-positive (ambiguous) samples require additional testing by another anti-HCV, RIBA, or HCV RNA assay.
참고문헌 (16)
- "Hepatitis C"[URL]
- "Guidelines for the screening care and treatment of persons with hepatitis c infection" (2014)[URL]
- European Association for Study of L, "EASL Clinical Practice Guidelines: management of hepatitis C virus infection", J Hepatol, 60, pp.392~420 (2014)
- Kamili S, "Laboratory diagnostics for hepatitis C virus infection", Clin Infect Dis, 55(Sl), pp.S43~S48 (2012)
- Seignères B, "Multicenter clinical evaluation of the new 3rd generation assay for detection of antibodies against hepatitis C virus on the VIDAS system", J Clin Virol, 78, pp.20~26 (2016)
- Alborino F, "Multicenter evaluation of a fully automated third-generation anti-HCV antibody screening test with excellent sensitivity and specificity", Med Microbiol Immunol, 200, pp.77~83 (2011)
- Kim S, "Clinical performance evaluation of four automated chemiluminescence immunoassays for hepatitis C virus antibody detection", J Clin Microbiol, 46, pp.3919~3923 (2008)
- Park Y, "Performance evaluation of the Vitros anti-hepatitis C virus antibody assay for use in clinical laboratories", Clin Biochem, 45, pp.175~177 (2012)
- Watterson JM, "Evaluation of the Ortho-Clinical Diagnostics Vitros ECi Anti-HCV test: comparison with three other methods", J Clin Lab Anal, 21, pp.162~166 (2007)
- Berger A, "Evaluation of the new ARCHITECT anti-HCV screening test under routine laboratory conditions", J Clin Virol, 43, pp.158~161 (2008)
- Kiely P, "The significance of third-generation HCV RIBA-indeterminate, RNA-negative results in voluntary blood donors screened with sequential third-generation immunoassays", Transfusion, 44, pp.349~358 (2004)
- Lemaire JM, "HCV RNA in blood donors with isolated reactivities by third-generation RIBA", Transfusion, 40, pp.867~870 (2000)
- Pawlotsky JM, "Significance of indeterminate third-generation hepatitis C virus recombinant immunoblot assay", J Clin Microbiol, 34, pp.80~83 (1996)
- Alter MJ, "Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention", MMWR Recomm Rep, 52, pp.1~13 (2003)
- Centers for Disease Control and Prevention, "Testing for HCV infection: an update of guidance for clinicians and laboratorians", MMWR Morb Mortal Wkly Rep, 62, pp.362~365 (2013)
- Yang R, "Performance evaluation and comparison of the newly developed Elecsys anti-HCV II assay with other widely used assays", Clin Chim Acta, 426, pp.95~101 (2013)